VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer

Inclusion Criteria: * Measurable stage IVA, stage IVB (with or without measurable disease) or recurrent (with or without measurable disease) endometrial carcinoma * NOTE: histologic confirmation of the original primary tumor is required; patients with the following histologic epithelial cell types are eligible: Endometrioid adenocarcinoma, serous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, carcinosarcoma, adenocarcinoma not otherwise specified (NOS) * NOTE: measurable disease is defined by Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.1) * Group A only: Largest tumor diameter =\< 5 cm * NOTE: Group B patients have no maximum tumor size * Absolute neutrophil count (ANC) \>= 1500/uL (obtained =\< 14 days prior to registration) * Platelet count (PLT) \>= 100,000/uL (obtained =\< 14 days prior to registration) * Hemoglobin \>= 10 g/dL (obtained =\< 14 days prior to registration) * Creatinine =\< 2.0 mg/dL (obtained =\< 14 days prior to registration) * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 2 x upper limit of normal (ULN) (obtained =\< 14 days prior to registration) * NOTE: if baseline liver disease, Child Pugh score not exceeding class A * Total bilirubin =\< 1.5 x ULN (obtained =\< 14 days prior to registration) * International normalized ratio (INR)/prothrombin time (PT), activated partial thromboplastin time (aPTT) =\< 1.4 x ULN (obtained =\< 14 days prior to …